J . Org. Chem. 1998, 63, 9533-9534
9533
Develop m en t of th e Hofm a n n
Rea r r a n gem en t of Nr-Tosyla sp a r a gin e
th r ou gh Ca lor im etr ic a n d NMR An a lysis
J oseph S. Amato,* Carl Bagner, Raymond J . Cvetovich,
Sue Gomolka, Frederick W. Hartner, J r., and
Robert Reamer
Departments of Process Research and Chemical Engineering
Research & Development, Merck Research Laboratories,
Rahway, New J ersey 07065
Received April 28, 1998
F igu r e 1. Fibrinogen receptor antagonist 1.
In tr od u ction
Looking to unravel the critical reaction parameters led
us to an examination of the calorimetry during the
reaction. Reactions were studied in a Mettler RC1 unit6
in which the heat flows were measured, samples were
withdrawn after each thermal event, and 1H and 13C
NMR measurements were performed. A cold solution of
sodium hypobromite (prepared by the addition of 1 equiv
of bromine to 1 equiv of aqueous sodium hydroxide) was
added to a cold solution of asparagine in aqueous sodium
hydroxide in the RC1 unit during which a -23.5 kcal/
mol heat flow was measured. A sample was withdrawn
to record the NMR. This sample gave spectra consistent
with expected N-bromo intermediate 3 but also consistent
with initial bromination of the tosylamide nitrogen
(which could transfer to the primary amide). After the
reaction was stirred at 0 °C for 15 min, external heat
was supplied from the jacket of the reactor, and the
calories of heat were measured during the heating. At
28 °C an exothermic event was observed in which a -64.7
kcal/mol heat flow was measured. The reaction temper-
ature rose to 35 °C while heat was removed from the
jacket of the reactor. After this thermal event a sample
was withdrawn. Examination by 1H and 13C NMR found
complete conversion of N-bromo intermediate 3 to the
imidazolidine derivative 4 via rapid intramolecular trap-
ping of the expected isocyanate intermediate. Imidazo-
lidine 4 can be isolated as a crystalline solid at this point
by cooling and acidifying with aqueous HCl.7
Recently, we had need to prepare kilogram quantities
of 2-(S)-(tosylamino)-â-alanine (6), an important inter-
mediate in the synthesis of potent fibrinogen receptor
antagonist 11 (Figure 1). This non-peptide molecule is
an active fibrinogen receptor antagonist that offers a
promising approach to the treatment of vascular diseases
through a mechanism of control of platelet aggregation.2
NR-Tosylaminoalanine (6) was prepared via the Hof-
mann rearrangement of NR-tosylasparagine. Although
this reaction is described in the literature,3 in our hands
the reaction was inconsistent, with yields oscillating
between 10 and 70%. Herein, we report a delineation of
the sequence of intermediates involved in the reaction
of sodium hypobromite with NR-tosylasparagine in aque-
ous sodium hydroxide. This study has resulted in an
understanding of the sequence of reaction intermediates
which has allowed greater control of the reaction param-
eters to achieve reproducibly high isolated yields (70%)
of NR-tosylaminoalanine (6) on scales ranging from 1 g
to 3 kg.
Resu lts a n d Discu ssion
The Hofmann rearrangement of NR-tosylasparagine (2)
has been described as a reaction that requires utmost
care to achieve the reported yield, and efforts to improve
the yield of the rearrangement were unsuccessful.4,5 We
observed similar problems with the reproducibility of this
venerable reaction with NR-tosylasparagine (2) when the
rearrangement was run on a kilogram scale, with sig-
nificant variability in yield (10-70%) and no discernible
differences noted in the procedure that was followed.
Heat was again supplied to the reaction from the jacket
of the reactor, and at 50 °C another thermal event was
observed, in which -13.5 kcal/mol heat flow was mea-
sured. NMR analysis of the reaction after this thermal
event was consistent with carbamic acid 5. Further
heating of the reaction to 70 °C produced a final thermal
event, in which -17.8 kcal/mol heat flow was measured.
NMR and HPLC analysis, with comparison with known
(1) Askew, B. C.; McIntyre, C. J .; Hunt, C. A.; Claremon, D. A.;
Gould, R.; Lynch, R. J .; Armstrong, D. J . Bioorg. Med. Chem. Lett. 1995,
5, 475.
(6) Mettler Instrument Co.
(2) (a) Ojima, I.; Charkravarty, S.; Dong, Q. Bioorg. Med. Chem.
1995, 3, 337. (b) Schror, K. Drugs 1995, 50, 7. (c) Cook, N. S.; Kottirsh,
G.; Zerwes, H.-G. Drugs Future 1994, 19, 135. (d) Nichols, A. J .; Vasko,
J . A.; Koster, P. F.; Valocik, R. E.; Samenen, J . M. In Cellular
Adhesion: Molecular Definition to Therapeutic Potential; Metcalf, B.
W., Dalton, B. J ., Poste, G., Eds.; Plenum Press: New York, 1994; pp
213-237.
(3) (a) Rudinger, J .; Poduska, K.; Zaoral, M. Collect. Czechoslov.
Chem. Commun. 1960, 25, 2022. (b) Hayashi, K.; Nunami, K.; Kato,
J .; Yoneda, N.; Kubo, M.; Ochiai, T.; Ishida, R. J . Med. Chem. 1989,
32, 289.
(7) Imidazolidine 4 was isolated from reaction mixtures after
warming to 40 °C: 1H NMR (500.13 MHz, DMSO-d6) δ 13.4 (br s, 1H),
7.86 (m, 2H), 7.66 (s, 1H), 7.41 (m, 2H), 4.86 (dd, J ) 10.3, 4.8, 1H),
3.71 (t, J ) 10.3, 1H), 3.26 (dd, J ) 10.3, 4.8, 1H), 2.40 (s, 3H); 13C
NMR (125.76 MHz, DMSO-d6) δ 171.3, 154.0, 144.2, 135.9, 129.2, 127.9,
56.3, 40.8, 20.9. In-situ data (referenced to external dioxane): 1H NMR
(399.87 MHz, NaOD) δ 7.36 (d, J ) 8.0, 2H), 6.93 (d, J ) 8.0, 2H),
3.98 (dd, J ) 10.4, 6.8, 1H), 3.14 (dd, J ) 12.1, 10.4, 1H), 2.77 (dd, J
) 12.1, 6.8, 1H), 1.92 (s, 3H); 13C NMR (100.55 MHz, NaOD) δ 180.6,
160.9, 145.9, 134.6, 130.5, 127.7, 62.5, 49.9, 21.5. Anal. Calcd for
C
11H12N2SO5: C, 46.47; H, 4.25; S, 11.28; N, 9.85. Found: C, 46.16;
(4) Aders, K.; Vesterager, E. Acta Chem. Scand. 1960, 14, 961.
(5) Shiba, T.; Koda A.; Kusamato, S.; Kanefko, T. Bull. Chem. Soc.
J pn. 1968, 41, 2748.
H, 4.11; S, 11.30; N, 9.68. This intermediate was shown to proceed to
product in NMR experiments consistent with the original NMR
experiments.
10.1021/jo980799l CCC: $15.00 © 1998 American Chemical Society
Published on Web 11/21/1998